<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82214">
  <stage>Registered</stage>
  <submitdate>14/08/2007</submitdate>
  <approvaldate>21/08/2007</approvaldate>
  <actrnumber>ACTRN12607000421437</actrnumber>
  <trial_identification>
    <studytitle>A clinical trial of a tooth cream in the repair of early dental decay.</studytitle>
    <scientifictitle>A three-month, double-blind, parallel-group, placebo-controlled randomized clinical trial to investigate the remineralizing capacity of casein phosphopeptide-amorphous calcium phosphate in a post-orthodontic population.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Caries</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tooth Mousse (containing casein phosphopeptide-amorphous calcium phosphate nanocomplexes (CPP-ACP). Tooth Mousse contains 10% w/v CPP-ACP. Dosage is 1ml Tooth Mousse twice daily for 12 weeks.</interventions>
    <comparator>Placebo. The placebo is a neutral mousse, identical in formulation to the Tooth Mousse, but not containing CPP-ACP.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate in vivo the capacity of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in Tooth Mousse to remineralize enamel white spot lesions in a post-orthodontic population as measured by change in Clinical Assessment score of a white spot lesion from baseline to 12 weeks.</outcome>
      <timepoint>Measurements will be taken at baseline, 4, 8 and 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate in vivo the capacity of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in Tooth Mousse to remineralize enamel white spot lesions in a post-orthodontic population as measured by change in Clinical Assessment score of a white spot lesion from baseline to 4 and 8 weeks.</outcome>
      <timepoint>Baseline to 4 and 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Undergoing fixed orthodontic treatment and due to have appliances removed during study period.
Exhibiting a minimum of two WSLs on the buccal surfaces of teeth 14 to 44 (or 15 to 45 when first premolars have been extracted) at time of recruitment.
Able to attend for four visits over a 12 week period.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a.Allergies to milk proteins.
b.Ulcerative mucosal conditions.
c.Chronic use of medication causing xerostomia.
d.Allergies to preservatives (or other ingredients) present in Tooth Mousse or placebo.
e.Unrestored dentinal caries in teeth 14 to 44 (or 15 to 45).
f.Pregnancy.
g.Any other illnesses/conditions that the Investigator deems could affect the study outcome.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed. All product had previously been de-idenitified, numbered and packaged at a central adminstration site according to the allocation schedule. The Investigator allocated the next available number to each new participant. In the case of medical emergency the treatment code could be accessed for a single subject without breaking the blind for other subjects.</concealment>
    <sequence>A computer generated block randomization schedule.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>46</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GC Corporation</primarysponsorname>
    <primarysponsoraddress>76-1 Hasunuma-Cho
Itabashi-Ku
Tokyo 174-8585</primarysponsoraddress>
    <primarysponsorcountry>Japan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>CRC Oral Health Science</fundingname>
      <fundingaddress>Central Office level 6
720 Swanston Street
Carlton
VIC 3053</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Halas Dental</sponsorname>
      <sponsoraddress>Unit 1-2 44 O'Dea Avenue, Waterloo 2017</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Melbourne HREC</ethicname>
      <ethicaddress>The University of Melbourne
Parkville 3010</ethicaddress>
      <ethicapprovaldate />
      <hrec>040863</hrec>
      <ethicsubmitdate>14/12/2004</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Denise Bailey</name>
      <address>Level 6, 720 Swanston Street
Carlton
VIC 3053</address>
      <phone>03 9341 1559</phone>
      <fax>03 9341 1559</fax>
      <email>dlbailey@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Denise Bailey</name>
      <address>Level 6, 720 Swanston Street
Carlton
VIC 3053</address>
      <phone>03 9341 1559</phone>
      <fax>03 9341 1559</fax>
      <email>dlbailey@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Denise Bailey</name>
      <address>Level 6, 720 Swanston Street
Carlton
VIC 3053</address>
      <phone>03 9341 1559</phone>
      <fax>03 9341 1559</fax>
      <email>dlbailey@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>